Literature DB >> 20449638

Induction of apoptosis in hepatocellular carcinoma Smmc-7721 cells by vitamin K(2) is associated with p53 and independent of the intrinsic apoptotic pathway.

Lu Li1, Zhiling Qi, Jin Qian, Fuyong Bi, Jun Lv, Lei Xu, Ling Zhang, Hongyu Chen, Renbing Jia.   

Abstract

Vitamin K(2) (VK(2)) can exert cell growth inhibitory effects in various human cancer cells. In this study, we investigated the cell growth inhibitory effects of VK(2) in hepatocellular carcinoma Smmc-7721 cells and the mechanisms involved. We found that VK(2)-inhibited cell proliferation in Smmc-7721 cells in a dose-dependent manner, and the IC50 of VK(2) in Smmc-7721 cells was 9.73 microM at 24 h. The data from flow cytometric analyses, DNA fragmentation assays, and caspase 3 activity assays revealed that apoptosis was the determining factor in VK(2) activity. Furthermore, a significant increase in p53 phosphorylation and protein level was exhibited in apoptotic cells treated with VK(2), although there were no changes in p53 mRNA expression. Bax expression was unaffected by VK(2) in Smmc-7721 cells. In addition, our study showed that caspase 3 was activated by caspase 8, not caspase 9, in Smmc-7721 cells treated with VK(2). In summary, these data suggested that VK(2) can inhibit the growth of Smmc-7721 cells by induction of apoptosis involving caspase 8 activation and p53. This apoptotic process was not mediated by the intrinsic apoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20449638     DOI: 10.1007/s11010-010-0476-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  30 in total

Review 1.  Apoptosis and leukaemia.

Authors:  Hugh J M Brady
Journal:  Br J Haematol       Date:  2003-11       Impact factor: 6.998

2.  FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.

Authors:  A M Chinnaiyan; K O'Rourke; M Tewari; V M Dixit
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

3.  A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain.

Authors:  M P Boldin; E E Varfolomeev; Z Pancer; I L Mett; J H Camonis; D Wallach
Journal:  J Biol Chem       Date:  1995-04-07       Impact factor: 5.157

Review 4.  Caspases: enemies within.

Authors:  N A Thornberry; Y Lazebnik
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

5.  Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells.

Authors:  K Miyazawa; M Yaguchi; K Funato; A Gotoh; Y Kawanishi; Y Nishizawa; A Yuo; K Ohyashiki
Journal:  Leukemia       Date:  2001-07       Impact factor: 11.528

Review 6.  Abnormalities of cell structures in tumors: apoptosis in tumors.

Authors:  Herman H Cheung; Vinay Arora; Robert G Korneluk
Journal:  EXS       Date:  2006

7.  Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei.

Authors:  Toshiko Sibayama-Imazu; Yukari Fujisawa; Yutaka Masuda; Toshihiro Aiuchi; Shigeo Nakajo; Hiroyuki Itabe; Kazuyasu Nakaya
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

8.  Apoptosis induction of vitamin K2 in lung carcinoma cell lines: the possibility of vitamin K2 therapy for lung cancer.

Authors:  Tsuyoshi Yoshida; Keisuke Miyazawa; Ikuma Kasuga; Tomohisa Yokoyama; Kazushige Minemura; Kenta Ustumi; Masahiro Aoshima; Kazuma Ohyashiki
Journal:  Int J Oncol       Date:  2003-09       Impact factor: 5.650

9.  Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation.

Authors:  Motoyuki Otsuka; Naoya Kato; Run-Xuan Shao; Yujin Hoshida; Hideaki Ijichi; Yukihiro Koike; Hiroyoshi Taniguchi; Masaru Moriyama; Yasushi Shiratori; Takao Kawabe; Masao Omata
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

Review 10.  The production of menaquinones (vitamin K2) by intestinal bacteria and their role in maintaining coagulation homeostasis.

Authors:  J M Conly; K Stein
Journal:  Prog Food Nutr Sci       Date:  1992 Oct-Dec
View more
  7 in total

1.  Metabolomics identifies the intersection of phosphoethanolamine with menaquinone-triggered apoptosis in an in vitro model of leukemia.

Authors:  Suganthagunthalam Dhakshinamoorthy; Nha-Truc Dinh; Jeffrey Skolnick; Mark P Styczynski
Journal:  Mol Biosyst       Date:  2015-09

2.  Enhanced therapeutic efficacy of vitamin K2 by silencing BCL-2 expression in SMMC-7721 hepatocellular carcinoma cells.

Authors:  Yuting Yao; Lu Li; He Zhang; Renbing Jia; Bo Liu; Xiaoping Zhao; Leilei Zhang; Guanxiang Qian; Xianqun Fan; Shengfang Ge
Journal:  Oncol Lett       Date:  2012-04-17       Impact factor: 2.967

Review 3.  Vitamin K and hepatocellular carcinoma: The basic and clinic.

Authors:  Xia Jinghe; Toshihiko Mizuta; Iwata Ozaki
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

4.  Evaluation of the antitumor effects of vitamin K2 (menaquinone-7) nanoemulsions modified with sialic acid-cholesterol conjugate.

Authors:  Jia Shi; Songlei Zhou; Le Kang; Hu Ling; Jiepeng Chen; Lili Duan; Yanzhi Song; Yihui Deng
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

5.  Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma.

Authors:  Yoshimichi Haruna; Noriko Hasegawa; Kazuho Imanaka; Seiichi Kawamoto; Atsuo Inoue
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

Review 6.  Research progress on the anticancer effects of vitamin K2.

Authors:  Fan Xv; Jiepeng Chen; Lili Duan; Shuzhuang Li
Journal:  Oncol Lett       Date:  2018-04-16       Impact factor: 2.967

7.  Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.

Authors:  Jian-Hong Zhong; Xin-Shao Mo; Bang-De Xiang; Wei-Ping Yuan; Jin-Fang Jiang; Gui-Sheng Xie; Le-Qun Li
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.